# Molidustat targets a synthetic lethal vulnerability in APC-mutant colorectal cancer through GSTP1 and PHD2 co-inhibition

Source: [eLife: latest articles](https://elifesciences.org/articles/110991) · 2026-11-10 · Life
Page: https://themorning.science/story/molidustat-targets-a-synthetic-lethal-vulnerability-in-apc-mutant-colorectal-can-5520ea72043172fa
Kind: research · Impact: medium

## In brief

- The study reports that molidustat targets a synthetic lethal vulnerability in APC-mutant colorectal cancer through co-inhibition of GSTP1 and PHD2.
- APC gene mutations are a defining feature of colorectal cancer and may create metabolic and stress adaptation requirements that could be exploited.
- Prolyl hydroxylase domain (PHD) inhibitors have been explored as a therapeutic approach, according to the abstract excerpt.

## Why it matters

The work proposes a possible targeted strategy for APC-mutant colorectal cancer, a common defining mutation, by exploiting a synthetic lethal dependency. The provided excerpt does not describe clinical testing or results beyond the abstract.

## Coverage

- [Molidustat targets a synthetic lethal vulnerability in APC-mutant colorectal cancer through GSTP1 and PHD2 co-inhibition](https://elifesciences.org/articles/110991) — eLife: latest articles, 2026-11-10

Tags: colorectal cancer, apc mutation, synthetic lethality, prolyl hydroxylase, molidustat, gstp1

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science